Jon Edwards

1 month ago | jdsupra.com | Rafi Allos |Jon Edwards |Laura Thompson

On March 28, 2025, Michael Tappin KC, sitting as a deputy judge of the High Court, refused to grant AstraZeneca (“AZ”) an interim injunction to restrain Glenmark from launching in the U.K. a generic version of its type 2 diabetes treatment, Forxiga® (dapagliflozin) for an estimated period of one to three months pending a trial decision and final order hearing in ongoing first instance revocation proceedings against AZ’s SPC that protects dapagliflozin.